- JP-listed companies
- Income statement
(219A) Income statement
Market cap
¥39.8B
P/E ratio
-18.7x
Heartseed develops regenerative heart muscle therapies using iPS cell-derived cardiac spheres to treat severe heart failure patients through medical institutions worldwide.
| 2019/10 | 2020/10 | 2021/10 | 2022/10 | 2023/10 | 2024/10 | 2025/10 | 2025/12 | |
| Revenue | - | - | 1,635 | 499 | 345 | 874 | 3,027 | 3,027 |
| Revenue growth (%) | - | - | - | |||||
| Gross profit | - | - | - | 499 | 345 | 874 | 3,027 | 3,027 |
| Gross margin (%) | - | - | - | |||||
| Operating margin (%) | - | - | - | |||||
| Operating expenses | - | - | - | 1,958 | 1,804 | 1,912 | 2,300 | 2,754 |
| Operating income | - | - | - | -1,459 | -1,460 | -1,039 | 726 | 272 |
| Income before tax | -505 | -970 | -255 | -1,410 | -1,457 | -819 | 691 | 289 |
| Pretax margin (%) | - | - | -15.6 | -282.6 | -422.5 | -93.7 | 22.8 | 9.5 |
| Provision for income taxes | - | - | - | 2 | 17 | -6 | 99 | 98 |
| Effective tax rate (%) | - | - | - | |||||
| Net income | -506 | -1,035 | -258 | -1,413 | -1,473 | -813 | 592 | 191 |
| Net income margin (%) | - | - | ||||||
| Earnings per share | -37,618.57 | -76,652.13 | -18,900.01 | -128.99 | -106.81 | -49.43 | - | 8.44 |
| Dividend per share | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | ||||
| EBITDA margin (%) | - | - | - | - |